Rapid detection of Staphylococcus aureus strains having reduced susceptibility to vancomycin using a chemiluminescence-based drug-susceptibility test

Journal of Microbiological Methods

Volumn 70, Issue 3, 2007, Pages 434-441

  Tajima, Yutaka ^a   Komatsu, Mitsutaka ^a   Ito, Teruyo ^a   Hiramatsu, Keiichi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Chemiluminescence; Drug susceptibility test; Vancomycin; Vancomycin intermediate Staphylococcus aureus (VISA)

Indexed keywords

VANCOMYCIN;

ARTICLE; BACTERIAL METABOLISM; BACTERIAL STRAIN; BACTERIUM DETECTION; CHEMOLUMINESCENCE; DRUG SENSITIVITY; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CHEMILUMINESCENT MEASUREMENTS; MICROBIAL SENSITIVITY TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

BACTERIA (MICROORGANISMS); STAPHYLOCOCCUS AUREUS;

EID: 34548130709     PISSN: 01677012     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mimet.2007.05.020     Document Type: Article

References (19)

1. Chesneau O., Morvan A., and Solh N.L. Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals. J. Antimicrob. Chemother. 45 (2000) 887-890
2. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 15th Informational Supplement M100-S15 (2005), Clinical and Laboratory Standards Institute, Wayne, Pa
3. Cui L., Ma X.X., Sato K., Okuma K., Tenover F.C., Mamizuka E.M., Gemmell C.G., Kim M.-N., Ploy M.-C., Solh N.E., Ferraz V., and Hiramatsu K. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41 (2003) 5-14
4. Fridkin S.K., Hageman J., McDougal L.K., Mohammed J., Jarvis W.R., Perl T.M., Tenover F.C., and Vancomycin-intermediate Staphylococcus aureus Epidemiology Study Group. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin. Infect. Dis. 36 (2003) 429-439
5. Kim M.-N., Pai C.H., Woo J.H., Ryu J.S., and Hiramatsu K. Vancomycin-intermediate Staphylococcus aureus in Korea. J. Clin. Microbiol. 38 (2000) 3789-3881
6. Henderson A.R. Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. Ann. Clin. Biochem. 6 (1993) 521-539
7. Hiramatsu K. Vancomycin resistance in staphylococci. Drug Resist. Updates 1 (1998) 135-150
8. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet 1 (2001) 147-155
9. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., and Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40 (1997) 135-136
10. Hood J., Edwards G.F.S., Cosgrove B., Curran E., Morrison D., and Gemmell C.G. Vancomycin-intermediate Staphylococcus aureus at a Scottish hospital. J. Infect. 40 (2000) A11
11. Manome I., Ikedo M., Saito Y., Ishii K., and Kaku M. Evaluation of a novel automated chemiluminescent assay system for antimicrobial susceptibility testing. J. Clin. Microbiol. 41 (2003) 279-284
12. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A6. 6th ed. (2003), National Committee for Clinical Laboratory Standards, Wayne, Pa.
13. Oliveira G.A., Dell'Aquila A.M., Masiero R.L., Levy C.E., Gomes M.S., Cui L., Hiramatsu K., and Mamizuka E.M. Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin. Infect. Control Hosp. Epidemiol. 22 (2001) 443-448
14. Ploy M.C., Grélaud C., Martin C., de Lumley L., and Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351 (1998) 1212
15. Ruef C. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection 32 (2004) 315-327
16. Walsh T.R., Bolmström A., Qwärnström A., Ho P., Wootton M., Howe R.A., MacGowan A.P., and Diekema D. Evaluation of current methods for detection of S staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39 (2001) 2439-2444
17. Walsh T.R., and Howe R.A. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu. Rev. Microbiol. 56 (2002) 657-675
18. Watanakunakorn C. Mode of action and in-vitro activity of vancomycin. J. Antimicrob. Chemother. 14 (1984) 7-18 (Suppl, D)
19. - production by Escherichia coli cells: application of rapid chemiluminescent assay to antimicrobial susceptibility testing. Microbiol. Immunol. 45 (2001) 333-340